NYSE$DNA
Ginkgo Bioworks Holdings · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Ginkgo Bioworks reported Q2 2025 results showing a net loss of $60.3 million on total revenue of $49.6 million.
For the three months ended June 30, 2025, Ginkgo recorded total revenue of $49.6 million, down from $56.2 million in the prior-year quarter, driven by lower Biosecurity revenue partially offset by growth in Cell Engineering. The company reported a net loss of $60.3 million and an operating loss of $65.5 million. Cash and cash equivalents stood at $203.6 million with total assets of $1.23 billion at quarter end.
- Total revenue declined 12% year-over-year to $49.6 million, with Cell Engineering revenue rising to $39.1 million while Biosecurity revenue fell to $10.5 million.
- Net loss narrowed significantly to $60.3 million from $217.2 million in Q2 2024, aided by sharply lower operating expenses following restructuring actions.
- Loss from operations improved to $65.5 million compared to $222.9 million in the prior-year quarter.
- Cash position remained solid at $203.6 million despite ongoing cash burn from operations.
Headline financials
Revenue & EPS history
Ginkgo Bioworks · Revenue · Quarterly
$55.7M
Revenue by segment
Ginkgo Bioworks · $49.6M total across 2 segments · Q2 2025
- Cell Engineering$39.1M—78.9%
- Biosecurity$10.5M—21.1%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-2.5%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-12.3%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+25.4%
Q4 2021
Best reaction
-20.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +1.9% | -17.5% | -19.4% | |
| Q4 2025 | +3.1% | -28.6% | -36.8% | |
| Q3 2025 | -20.8% | -26.0% | -18.1% | |
| Q1 2025 | +14.8% | +28.8% | +17.7% | |
| Q4 2024 | -11.5% | -22.2% | -40.5% | |
| Q3 2024 | -1.8% | -27.3% | +17.9% | |
| Q2 2024 | -1.5% | +2.6% | -48.4% | |
| Q1 2024 | -14.8% | -3.4% | -42.4% | |
| Q4 2023 | -15.1% | -24.3% | -23.7% | |
| Q3 2023 | -18.2% | -16.9% | -11.7% | |
| Q2 2023 | -15.9% | -13.9% | +0.0% | |
| Q1 2023 | -2.9% | -3.6% | +35.0% | |
| Q4 2022 | -4.8% | -7.5% | -9.5% | |
| Q3 2022 | -6.3% | -23.2% | -41.1% | |
| Q2 2022 | +3.0% | -21.5% | -15.4% | |
| Q1 2022 | +3.0% | -1.9% | -2.6% | |
| Q4 2021 | +25.4% | +14.8% | -6.3% | |
| Q4 2019 | -0.3% | -0.5% | -11.8% | |
| Q3 2021 | +8.5% | +4.3% | -15.9% | |
| Q2 2021 | -0.1% | -0.3% | +1.5% | |
| Q1 2021 | +0.0% | -0.2% | +0.2% | |
| Q4 2020 | +0.0% | -0.2% | +0.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro